Abstract
Objective: The patients with advanced-stage ovarian cancer have higher factors complicating surgery; thus, the best choice for them is surgery with chemotherapy with six cycles of adjuvant chemotherapy. Generally, chemotherapy can be evaluated in various ways, phsychal examination, radiology examination, and laboratory examination. This study aims is to examine if the measurement of the platelet/lymphocyte ratio (PLR) and neutrophil/lymphocyte ratio (NLR) can be used to predict a patient’s response to chemotherapy. Methods:Analytic observational study with a case-control design conducted in the Dr. Hasan Sadikin Hospital in Bandung from 2017 to 2018. This study used the medical record of ovarian cancer patients with post-surgery complete blood counts and histopathological reports. The sample size was determined based on the categorical test’s statistical calculation to obtain a total number of at minimal 90 samples. All the study subjects who had undergone complete chemotherapy were followed up for 6 months. Their response to chemotherapy was assessed with a clinical examination, ultrasonography, and a CA-125 blood test every 3 months. Results:In 2017–2018, 504 patients were diagnosed with ovarian cancer at the Dr. Hasan Sadikin Hospital in Bandung, Indonesia. After reassessment, 116 patients had stage I to III ovarian cancer and underwent cytoreduction followed by platinum chemotherapy. The age, cancer stage, and types of epithelial cells in the platinum-sensitive and platinum-resistant patients were characterized. There were significant differences between the two groups in age and cancer stage characteristics (p < 0.05). The increase in platelet/lymphocyte (p = 0.003) and neutrophil/lymphocyte ratios (p = 0.026) are associated with the increase in the response to platinum chemotherapy against epithelium-based cancers. Conclusion:A patient’s NLR and PLR are strongly associated with his response to chemotherapy.
Highlights
Ovarian cancer, the 8th most common cancer in a woman, has increased by more than 20% since 2012 globally (Sung et al, 2021)
This study aims is to examine if the measurement of the platelet/lymphocyte ratio (PLR) and neutrophil/lymphocyte ratio (NLR) can be used to predict a patient’s response to chemotherapy
In 2017–2018, 504 patients were diagnosed with ovarian cancer at the Dr Hasan Sadikin Hospital in Bandung, Indonesia
Summary
The 8th most common cancer in a woman, has increased by more than 20% since 2012 globally (Sung et al, 2021). In 2018, the number of new ovarian cancer cases exceeded 300,000. About 80%–90% of the ovarian malignancies are due to epithelial differentiation, with 19.6%–35% incidence (Zhang et al, 2019). Cytoreduction surgery is the primary treatment for ovarian carcinoma. Patients with early-stage ovarian cancer are most suitable for cytoreduction. The patients with advanced-stage ovarian cancer have higher factors complicating surgery; the best option is surgery with chemotherapy with six cycles of adjuvant chemotherapy (Querleu et al, 2017). Chemotherapy with platinum/carboplatin combined with paclitaxel is still the standard chemotherapy in ovarian carcinoma in Hasan Sadikin Hospital Bandung
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
